MGMT and malignant glioma: Multiple studies have now validated the clinical importance of MGMT expression as a marker for resistance to temozolomide in the treatment of malignant glioma (Jaeckle et al, 1998; Esteller et al, 1999, 2000; Hegi et al, 2005; Chinot et al, 2007).